8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Published . Updated .
Filed: 2026-10-07 AccNo: 0001628280-26-065291 Size: 590 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Directly affected
- SYRE Spyre Therapeutics
Named in this report.
Indirectly affected
- SPY SPDR S&P 500
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond
Long-term U.S. government bonds
- QQQ Invesco QQQ
Large technology stocks
- GLD SPDR Gold Shares
Gold can move with the broad market
Price reaction, T-5 to T+3
Filed: 2026-10-07 AccNo: 0001628280-26-065291 Size: 590 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Spyre Therapeutics (SYRE) since this story, compared with the market
Since the first closing price after “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer),” Spyre Therapeutics (SYRE) is +5.88%. The S&P 500 fund (SPY) is -0.94% over the same days, a +6.82% difference versus the market.
Who gains and who loses around Spyre Therapeutics (SYRE)
Companies tied to this story
- SYRE Spyre Therapeutics
Spyre Therapeutics (SYRE) is linked, with no stored direction, high confidence in the 7 Oct 2026 story “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> SYRE
How “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)” reaches Spyre Therapeutics (SYRE)
Spyre Therapeutics (SYRE) is the company in “8-K - Spyre Therapeutics, Inc. (0001636282) (Filer),” the 7 Oct 2026 this story story.
Spyre Therapeutics (SYRE) is on the page because SEC 8-K filing -> direct issuer disclosure -> SYRE
Dates and price levels for Spyre Therapeutics (SYRE)
SYRE traded between 77.09 and 91.41 across 11 sessions. The latest close on file is 84.61.
How strong the case is around Spyre Therapeutics (SYRE)
14 out of 100
“8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.